UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/007,693	12/05/2001	Ajay Bhatia	210121.515C2	1153

500 7590 11/21/2002

SEED INTELLECTUAL PROPERTY LAW GROUP PLLC
701 FIFTH AVE
SUITE 6300
SEATTLE, WA 98104-7092

EXAMINER	
BASKAR, PADMAVATHI	
ART UNIT	**PAPER NUMBER**
1645	7

DATE MAILED: 11/21/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/007,693	BHATIA ET AL.	
	Examiner	Art Unit	
	Padmavathi v Baskar	1645	

-- The MAILING DATE of this communication app ars on th cover she t with the corr spond nce address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☐ Responsive to communication(s) filed on _____ .

2a)☐ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *1-18* is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☐ Claim(s) _____ is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☒ Claim(s) *1-18* are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11)☐ The proposed drawing correction filed on _____ is: a)☐ approved b)☐ disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12)☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____ .

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) ☐ The translation of the foreign language provisional application has been received.

15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ .
4) ☐ Interview Summary (PTO-413) Paper No(s). _____ .
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other: .

RESTRICTION

1. Restriction to one of the following groups of invention is required under 35 U.S.C. 121:

I. Claims 1, 4, 5, 9, 12, drawn to DNA, host cell, vaccine and pharmaceutical composition classified in class 536, subclass 23.7. Further restriction to one SEQ.ID.NO required (see paragraph # 3).

II. Claims 2, 3, 8, 12 drawn to polypeptide classified in class 530, subclass 350. . Further restriction to one SEQ.ID.NO required (see paragraph # 3).

III. Claims 6 and 12 drawn to an antibody and a composition comprising antibody classified in class 530, subclass 388.6. Further restriction to one SEQ.ID.NO required (see paragraph # 3).

IV. Claims 7 and 17 drawn to a method of detecting Chlamydia infection using binding agent and a diagnostic kit classified in class 435, subclass 7.22. . Further restriction to one SEQ.ID.NO required (see paragraph # 3).

V. Claims 10-12 drawn to a method for stimulating and/or expanding T-cells and T-cell population. classified in class 436, subclass 500. . Further restriction to one SEQ.ID.NO required (see paragraph # 3).

VI. Claim 13 drawn to a method for inducing immune response classified in class 424, subclass 270.1. . Further restriction to one SEQ.ID.NO required (see paragraph # 3).

VII. Claim14 drawn to a method for treating Chlamydia infection using nucleic acid classified in class 424, subclass 263.1. . Further restriction to one SEQ.ID.NO required (see paragraph # 3).

VIII. Claim 14 drawn to a method for the treatment of Chlamydia infection using peptide classified in class 424, subclass 184.1. Further restriction to one SEQ.ID.NO required (see paragraph # 3).

IX. Claim 18 drawn to a method for the treatment of Chlamydia infection administering T-cells. classified in class 424, subclass 185.1. Further restriction to one SEQ.ID.NO required (see paragraph # 3).

X. Claims 15 and 16 drawn to a method of detecting Chlamydia infection using nucleic acid and a diagnostic kit. classified in class 435, subclass 6. . Further restriction to one SEQ.ID.NO required (see paragraph # 3).

2. The inventions are distinct, each from the other because of the following reasons:

Group I is directed to DNA, which consists of nucleic acids. Groups II is directed polypeptides, which are made of amino acids; Invention III is drawn to an antibody and is distinct from Inventions I-II since it has an inherent affinity, avidity, and specificity that DNA or a simple protein is not capable of expressing. These products are different to each other structurally, biochemically and functionally.

Groups IV-X are different methods utilizing different products with different structure and biological properties. Inventions IV and X are drawn to different methods detecting of Chlamydia

infection utilizing different biological reagents such as antibodies and nucleic acids respectively. Inventions V-IX are drawn to methods for inducing immune response and treatment of Chlamydia infection utilizing different products namely proteins, nucleic acids, antibodies and T-cells. Thus Inventions IV, V, VI, VII VIII, IX and X are different methods using different biological reagents, different method steps which result in different outcome

Distinct Inventions

3. For each group of inventions I-X above, restriction to one of the following SEQ.ID.NO is also required under 35 USC 121. Therefore, election is required of one of inventions I - X and one of SEQ ID NO: 1 - SEQ ID NO: 157.

Inventions SEQ ID NO: 1 - SEQ ID NO: 157 are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions; represent structurally different polypeptides and the polynucleotides encoding them. Therefore, where structural identity is required, such as for hybridization or expression, the different sequences have different effects. Thus, each sequence is unique and patentably distinct since each sequence has a different structure with specific amino acid or nucleic acid and is identified by a specific SEQ.ID.NO. Restriction is deemed proper because these products appear to constitute patentably distinct inventions. Applicant is required under 35 U.S.C. 121 to elect a single disclosed SEQ.ID.NO from any group elected.

4. Invention II is related to inventions V, VI, VIII and IX as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the protein of Group II can be used in immunoaffinity chromatography methods for purifying antibodies and need not be used in the inventions V, VI, VIII and IX

5. Invention I is related to inventions VI, VII, IX and X as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the DNA of Group I can be used to prepare hybrid clones of Chlamydia and need not be used in the inventions VI, VII, IX and X

6. Invention III is related to inventions IV as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the antibody of Group III can be used in immunoaffinity chromatography for purifying antigens and need not be used in the inventions IV.

7. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their separate classification and their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

8. Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

9. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

10. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Padmavathi v Baskar whose telephone number is (703) 308-8886. The examiner can normally be reached on M-F (6:30A.M-4: 00 P.M.) First Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on (703) 308-3909. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

P. Baskar Ph.D.
10/18/02

MARK NAVARRO
PRIMARY EXAMINER